Compare WBX & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WBX | ACOG |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | Spain | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.0M | 115.5M |
| IPO Year | N/A | N/A |
| Metric | WBX | ACOG |
|---|---|---|
| Price | $3.02 | $5.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $9.00 | ★ $18.00 |
| AVG Volume (30 Days) | 26.7K | ★ 84.0K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $174,593,453.00 | $7,427,199.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $33.37 | $143.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.85 | $3.75 |
| 52 Week High | $14.40 | $11.54 |
| Indicator | WBX | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 32.36 | 34.30 |
| Support Level | $2.90 | $5.66 |
| Resistance Level | $3.21 | $6.74 |
| Average True Range (ATR) | 0.25 | 0.40 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 12.15 | 4.57 |
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.